Wire · opportunities
'Miracle drug' used by Sasse receives FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The FDA approved Rasonque, a new drug for metastatic pancreatic cancer that nearly doubles median survival time, offering a significant treatment advance in the US. The drug, developed by Revolution Medicines, is a once-daily oral therapy costing approximately $39,800 per month, with co-pay assistance available.
This Wire brief sits within Fusion42's coverage of Health, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Your oncology startup must move fast to align with Rasonque’s FDA approval as payers and providers will revise treatment protocols. This drug sets a new survival benchmark, forcing competitors and partners to reassess pancreatic cancer therapies immediately.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics